{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50","upperLimit":"93","value":"68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"following the 3-phase comprehensive treatment approach including induction with BD, followed by risk adapted HDM/ASCT, followed by consolidation/maintenance therapy with BD in patients with AL amyloidosis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with newly diagnosed AL amyloidosis","id":"OG000","title":"Amyloidosis"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Progression Free Survival at 24 Months","type":"SECONDARY","unitOfMeasure":"percentage of patients"}